(United States, Nevada, Las Vegas), DelveInsight’s, “Diabetic Retinopathy – Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Diabetic Retinopathy Pipeline Report
-
Over 50+ companies and 55 + pipeline drugs in Cardiovascular Calcification are in various stages of development, and their anticipated acceptance in the Cardiovascular Calcification market would significantly increase market revenue.
-
Leading Cardiovascular Calcification companies developing novel drug candidates to improve the Cardiovascular Calcification treatment landscape include Novartis, Regenxbio, OcuTerra Therapeutics, Ocular Therapeutix, Bayer, and many others
-
Promising Cardiovascular Calcification pipeline therapies in various stages of development include Brolucizumab, RGX 314, OTT-166, and many others
Diabetic Retinopathy Overview
Diabetic retinopathy is a major complication of diabetes mellitus (DM), which remains a leading cause of visual loss in working-age populations. The retina contains photoreceptor cells that function in the process of visual transduction, i.e., transforming light signals to nerve impulses eventually transmitted from the optic nerve to the brain forming an image. In mammals, the retina is supplied with oxygen and nutrients by the retinal and choroidal circulatory systems, and most major causes of retinopathy involve damage to these systems. The retinal circulation supplies the inner (towards the center of the eye) half of the retina and the choroidal circulation supplies the outer half of the retina. Light must pass through the retinal capillaries (and some neuronal layers) before striking the photoreceptors (see Figure). The choroid lies behind the retinal pigment epithelium (RPE). The RPE, the macula, and the anterior segment of the optic nerve depend on the choroidal circulation for oxygen and nutrients (see Figure). Lack of sufficient blood flow in the retinal circulation can lead to optic neuropathy and vision loss. Rupture of the retinal capillaries can lead to bleeding into the vitreous humor (vitreous hemorrhage) and vision loss.
Diabetic Retinopathy Pipeline Analysis: Drug Profile
KSI-301: Kodiak Sciences
KSI-301 is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in the secretion of vascular endothelial growth factor (VEGF), which causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes of patients with diabetic retinopathy. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently approved anti-VEGF agents. However, many patients are lost to follow-up due to the frequent injections and real-world outcomes in diabetic retinopathy do not meet the promise shown in clinical trials. By extending on the mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in the Phase III stage of development towards a once-every-four to six-month treatment regimen – a possible game-changer that may provide the opportunity for real prevention.
Brolucizumab: Novartis
Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics. The proprietary, innovative structure results in a small molecule (26 kDa) with potent inhibition of and high affinity to, all VEGF-A isoforms. In preclinical studies, brolucizumab inhibited the activation of VEGF receptors through the prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema, and improve vision in patients with chorioretinal vascular diseases. Currently, the drug is in the Phase III stage of development to treat Diabetic Retinopathy.
Discover more about the emerging Diabetic Retinopathy drugs @ Diabetic Retinopathy
Diabetic Retinopathy Pipeline Therapies and Key Companies
-
KSI-301: Kodiak Sciences
-
Brolucizumab: Novartis
-
RGX 314: Regenxbio Inc.
-
OTT-166: OcuTerra Therapeutics
And many others
Diabetic Retinopathy Pipeline Therapeutics Assessment
Phases
DelveInsight’s Report covers around 33+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Subcutaneous
-
Intravenous
-
Intramuscular
Molecule Type: Products have been categorized under various Molecule types such as
-
Bispecific Antibody
-
Peptides
-
Small molecule
-
Gene therapy
Product Type: Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Diabetic Retinopathy Pipeline Report
-
Coverage: Global
-
Key Diabetic Retinopathy Companies: Novartis, AbbVie, Janssen Biotech, InflaRx, Ambulero, and many others.
-
Key Diabetic Retinopathy Pipeline Therapies: Upadacitinib, Belimumab, Secukinumab, and many others
Find out more about the Diabetic Retinopathy treatment options in development @ Diabetic Retinopathy Clinical Trials
Table of Contents
1. Diabetic Retinopathy Introduction
2. Diabetic Retinopathy Summary
3. Diabetic Retinopathy Overview
4. Diabetic Retinopathy Pipeline Therapeutics
5. Diabetic Retinopathy (Phase III)
6. Diabetic Retinopathy (Phase II)
7. Diabetic Retinopathy (Phase I/II)
8. Diabetic Retinopathy Products
9. Diabetic Retinopathy Discovery Stage Products
10. Diabetic Retinopathy Therapeutic Assessment
11. Diabetic Retinopathy Inactive Products
12. Diabetic Retinopathy Collaborations Assessment- Licensing / Partnering / Funding
13. Diabetic Retinopathy Unmet Needs
14. Diabetic Retinopathy Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services